UK markets closed

Stratec SE (0RAR.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
87.87+2.67 (+3.13%)
At close: 06:10PM GMT
Full screen
Previous close85.20
Open87.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range86.29 - 88.60
52-week range86.29 - 88.60
Volume1,089
Avg. volumeN/A
Market cap10.504M
Beta (5Y monthly)0.30
PE ratio (TTM)0.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

    EQS-News: STRATEC SE / Key word(s): ConferenceSTRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 15.12.2022 / 15:34 CET/CESTThe issuer is solely responsible for the content of this announcement.STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Birkenfeld, December 15, 2022STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at

  • EQS Group

    NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

    EQS-News: STRATEC SE / Key word(s): PersonnelNEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE 01.12.2022 / 16:14 CET/CESTThe issuer is solely responsible for the content of this announcement.NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE Birkenfeld, December 1, 2022The Supervisory Board of STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) has decided to extend the company’s Board of Management with a further member and appointed Dr. Georg Bauer to the Board with r

  • EQS Group

    STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022

    EQS-News: STRATEC SE / Key word(s): Quarter Results/ForecastSTRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022 03.11.2022 / 06:55 CET/CESTThe issuer is solely responsible for the content of this announcement.STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022 Sales in 9M/2022 -7.9% to € 207.7 million (9M/2021: € 225.4 million); constant currency: -11.7% Adjusted EBIT of € 38.1 million in 9M/2022 (9M/2021: € 48.7 million) Adjusted EBIT margin of 18.3% (9M/2021: 21.6%) at upper end of target